MDxHealth (MDXH) Projected to Post Earnings on Wednesday

MDxHealth (NASDAQ:MDXH) is projected to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect MDxHealth to post earnings of ($0.21) per share and revenue of $22.67 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

MDxHealth Trading Down 0.5 %

NASDAQ:MDXH opened at $1.86 on Friday. MDxHealth has a 12 month low of $1.55 and a 12 month high of $3.85. The firm has a market capitalization of $87.96 million, a PE ratio of -1.22 and a beta of 1.34. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. The business’s 50-day moving average is $2.05 and its two-hundred day moving average is $2.22.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MDXH. Lake Street Capital began coverage on MDxHealth in a research report on Thursday, October 31st. They set a “buy” rating and a $7.00 target price on the stock. Piper Sandler dropped their target price on MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.